UK MHRA Outlines 'Safety Feature' Challenges Facing Wholesale Sector
At a recent MHRA symposium, wholesalers were treated to a presentation on possible hurdles they may encounter as the EU Falsified Medicines Directive brings in a new product verification system from February next year.
You may also be interested in...
The MHRA has set out its position on those aspects of the new “safety feature” rules for prescription drugs where member states have flexibility to choose their options, such as the information to be included in the “unique identifier” and the conditions for “checking out” medicines from the verification system. The European Medicines Verification System is being introduced as part of the EU Falsified Medicines Directive.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.